IBC Meeting Minutes Cleveland Clinic Florida Research and Innovation Center

Date:		Location:	
July 17 th , 2025		Zoom	
IBC Member Attendance:			
	⊠ Li, K	un	⊠ Such, Kimberly
☐ Champer, Dylan (BSO)	⊠ Hajja	r, Adeline	☑ Judd, Leslie
⊠ Tavakoli, Sara	□ O'Co	nnor, Christine	☐ Doud, Melissa
Stolley, Michael			
Guests: Amanda Dragan*, Anna Riets Meyer* *Cleveland Clinic Main Campus	ch*, Abby	Bifano*, Anthony	Santilli*, Jennifer Veillette*, Nikki
Call To Order:		Adjourn:	
2:31 pm		3:40 pm	

I. Review of June 9th, 2025 Meeting Minutes

Committee Comments: None			
Motion:	For:	Against:	Abstain:
Approval	8	0	2

II. Administrative Business

a. Committee presented with personnel additions.

III. Non-Clinical Research:

a. Amendments:

	Protocol ID:	PI:	Biosafety Level:	NIH Cat.:
	FLIBC001	Gack	BSL-1, BSL-2,	III-F-1, III-F-2, III-
Basic Research			BSL-2+, ABSL-2	F-3, III-F-8, III-D-
Amendment # 1				1-a, III-D-2-a, III-
				D-3-a, III-D-4-b,
				III-D-7, III-E
Project Titles:	_			
Regulation of Host A	ntiviral Innate I	mmunity		

NIH (2023): 5DP1AI	Associated Grant Numbers: NIH (2023): 5DP1AI169444-03, 5R01 AI148534-04, 5R01 AI165502-03, 5 R37 AI087846- 14, 1 R21 AI174534-01A1; Non-NIH Funding							
Summary of Approx Propagation of recom administration of viru recombinant and wild analyses, administrati derived materials.	binant uses and type S	and non- l viral tra ARS-Co	ansduced V-2 viru	l cells is, inf	s <i>in vivo</i> ; (Tection of o	Generation a cell lines an	and propag d experime	ation of ental
Requested Additions • Addition of B		_	y space to	o the	protocol.			
Function/Nature of R ⊠ N/A □ Oncogene □ Immunomodulatory Species of Recombin ⊠ N/A □ Human □	☐ Tun☐ Toxi	nor Supp n □ An nes to be	ressor Ge tibiotic R Expresse	ene Lesista	☐ Structur	porters \square (•	timicrobial
Committee Commer	its: No	ne						
Facilities, Procedure ⊠ Yes □ No	s, and	Safety F	Practices	Rev	iewed (Y/	N):		
PI/Supervisor Train ⊠ Yes □ No	ing (Y/	N):			Handler ⊠ Yes	Training (Y/N):	
Motion: Approval		Fo	or: 7	A	gainst: 0	Abstain:	Recuse:	Not Present:
					1			
Basic Research Amendment # 2 Protocol ID: FLIBC011 Cao Biosafety Level: BSL-1, BSL-2, BSL-2+, ABSL1, ABSL-2								
Project Titles: Live-cell imaging of complex biological parts		-	_			inment in o	rder to inte	rrogate the
Associated Grant No N/A	umbers	S:						
Summary of Approx Imaging of live and fi materials.			ntaining	Risk	Group 1	or 2 agents;	human-de	rived

Requested Additions	/Chan	ges:							
Addition of B	SL-1 1	aboratory	space t	o the	protocol.				
Function/Nature of Ro				_			1:		
⊠ N/A □ Oncogene						_	_	itimicrobiai	
☐ Immunomodulatory	☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Other								
Species of Recombina	ant Ger	nes to be	Express	ed:					
\boxtimes N/A \square Human \square			-		□ Viral [☐ Other			
Committee Commen	ts: No	ne							
Facilities, Procedure	a and	Safaty D	maatiaas	Dox	iowad (V	/NI) •			
Yes	s, and	Salety F	ractices	nev	ieweu (17	11):			
PI/Supervisor Traini	ing (Y/	N):			Handlei	r Training (Y/N):		
⊠ Yes □ No	- (- ·).			⊠ Yes	□ No	. – 1 – 1,71		
Motion:		Fo		A	gainst.	Abstain:	Recuse:	Not	
Approval		7 T		A	gainst: ()	Abstain:	0	Present:	
		,				1	V	0	
Davis Davis de	Proto	col ID:	PI:	•	Biosaf	ety Level:	NI	H Cat.:	
Basic Research Amendment # 3	FLIE	3C015	Thon	nas	BSL-	1, BSL-2,		N/A	
					B	SL-2+			
Project Titles:			_						
Sample preparation, c			low-cyt	omet	ric analysi	is of unfixed	l samples r	requiring	
BSL-2/BSL-2+ contain	ınment	•							
Associated Grant Nu	ımher								
N/A	HIIDCI	•							
Summary of Approv	ed Ite	ms:							
Sample preparation, c			low cyto	ometi	ic analysi	s of fixed a	nd unfixed	samples	
containing Risk Grou	p 2/2+	agents. A	All agent	has t	o be appro	oved by the	IBC for ea	ch	
investigator, before us			oment; F	Iuma	n derived	materials.			
Requested Additions		_		_					
Addition of B	SL-1 l	aboratory	space t	o the	protocol.				
Function/Nature of Re	aaamh:	inant Gar	os to bo	Evn	ossad.				
				-		ral 🗆 Signa	ling \Box An	ntimicrobial	
N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimicrobial □ Immunomodulatory □ Toyin □ Antihictic Registerace □ Reporters □ Other									
☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Other									
Species of Recombina	Species of Recombinant Genes to be Expressed:								
N/A □ Human □			-		□ Viral [☐ Other			
Committee Commen	ts: No	ne							

Facilities, Procedure	s, and	Safety F	ractices	Rev	iewed (Y	/N):				
⊠ Yes □ No										
PI/Supervisor Traini	ing (Y/	N):			Handler Training (Y/N):					
⊠ Yes □ No					⊠ Yes	□ No				
Motion:		Fo	v.	A .	gainst:	Abstain:	Recuse:	Doggan Not		
Approval		1.0		A	gamst. ()	Abstain.	necuse.	Present:		
		, 0 1 0								
	Droto	col ID:	PI:		Piosof	ety Level:	NI	H Cat.:		
Basic Research		COLID:	Zhao			1, BSL-2,		- а, III-D-2а,		
Amendment # 4	1 LIL	, C008	Ziia	3		+, ABSL-2		-a, III-D-2a, -a, III-D-4-		
Amenument # 4					DSL-2	, ADSL-2		, III-E		
Project Titles:			l		1		1 0,	,		
Manipulation of Innat	e Imm	unity and	l Metabo	lism	by Viruse	es and Cance	ers			
Trainparation of innat	- 1111111	and and	_ 1,15,400	-15111	- j , 11 use	una cuno				
Associated Grant Nu	ımbers	:								
NIH/NIDCR DE0289	973, N	IH/NID	CR DEO	3363	2					
Summary of Approv	ed Iter	ns:								
Generation of replicat			ntivirus,	trans	sduction o	f tissue cult	ure cells ar	nd		
administration of trans	sduced	cells to	mice; EE	3V+,	KSHV+,	and KSHV-	+/EBV+ ce	ll lines,		
non-K12 E.coli, Mam	malian	express	ion vecto	rs; H	luman-dei	rived materi	als.			
Requested Additions	/Chan	ges:								
Addition of Tr	issue ci	ulture ce	ll line an	d adr	ninistratio	on route to n	nice			
Function/Nature of Re	<u>ecombi</u>	nant Gei	nes to be	Expi	essed:					
⊠ N/A □ Oncogene	□ Tum	or Supp	ressor G	ene	☐ Structui	ral 🗆 Signa	ling 🗆 An	timicrobial		
☐ Immunomodulatory	☐ Toxi	n □An	tibiotic R	esista	nce 🗆 Re	porters \square C	Other			
Species of Recombina			_							
\boxtimes N/A \square Human \square	l Murin	e □ Rat	☐ Bacte	rial	□ Viral [☐ Other				
~ ~										
Committee Commen	its: No	ne								
E 1141 D 1				D	• 107	/NT)				
Facilities, Procedure	s, and	Salety P	ractices	Kev	iewea (Y/	/N):				
⊠ Yes □ No	· (\$7.1	NT)			TT 11	TD	X / / N /)			
PI/Supervisor Traini	ing (Y/	N):				r Training (Y/N):			
	1				⊠ Yes	□ No		NI - 4		
Motion:		Fo	r:	A	gainst:	Abstain:	Recuse:	Not Presents		
Approval			7		0	1	0	Present:		
						1		U		

Basic Research	Protocol ID:	PI:	Biosafety Level:	NIH Cat.:
Amendment # 5	FLIBC017	Li	BSL-3, ABSL-3	III-D-1-b, III-D-4-b
Project Titles:				

Host-pathogen interactions during Coronavirus infection								
Associated Grant No Non-NIH Funding	umbers	S:						
Summary of Approx	ed Ite	ms:						
Acquisition and Prop			and recon	nbina	ant human	and mouse	SARS-Co	V-2 strains.
infection of tissue cul								. = :::::::::::::::::::::::::::::::::::
Requested Additions					,			
Adding new of		_	ree strain	s of l	MERS to 1	the protocol		
1 rading new v		os ana un	ice strain	.5 OI 1	VILIO 10	ine protocor		
Function/Nature of R	ecombi	nant Ger	nes to be	Expr	essed:			
						al □ Sional	ling □ An	timicrobial
☐ Immunomodulatory						•	•	tillineroolar
	□ 10A1	п шлп	moione ix	CSISIA		porters \square C	, till Ci	
Species of Recombin	ant Ger	nes to he	Expresse	-d·				
			_		□ Viral □	7 Other		
⊠ IVA □ Human □	ıvıuı iii	c ⊔ Kai	⊔ Васи	1141	□ viiai L			
Committee Commer	ıts:							
Clarify experi		usage fo	r new ๑๓	ent a	nd cell lin	ies		
• Confirm cell l				,CIII u	iid ceii iii	ies		
• Confirm cen i	ine inic	ormanon						
Facilities, Procedure	es, and	Safety P	Practices	Rev	iewed (Y/	N):		
⊠ Yes □ No	,					- ')'		
PI/Supervisor Train	ing (Y/	N):			Handler	Training (Y/N):	
⊠ Yes □ No	8 (/).			⊠ Yes	□ No		
Motion:								
Approved with		Fo	r:	A	gainst:	Abstain:	Recuse:	Not
	Administrative Revisions 7 0 1 0 Present:							
	Proto	col ID:	PI:		Biosaf	ety Level:	NI	H Cat.:
Basic Research		3C022	Sperar			1, BSL-2,		-D-1-a
Amendment # 6		-	BSL-1, BSL-2, III-D-1-a BSL-2+, BSL-3,					

Project Titles:

Spatial and transcriptional response to viral infections at barrier tissue sites

Associated Grant Numbers:

Non-NIH Funding

Summary of Approved Items:

Propagation of non-recombinant Vesicular Stomatitis Virus, West Nile Virus, Chikungunya Virus, and SARS-CoV-2 strains; administration *in vivo*. Propagation of recombinant Vesicular Stomatitis Virus; Acquisition of inactivated Ebola Virus and inactivated Lassa Virus samples for histology and sequencing; human-derived materials.

ABSL-2, ABSL-3

Adding valid suspension us	ation ar	nd inactiv	_			_	fected sing	tle cell
Function/Nature of R ⊠ N/A □ Oncogene □ Immunomodulatory	□ Tun	nor Supp	ressor G	ene	☐ Structur	_	_	timicrobial
Species of Recombin ⊠ N/A □ Human □			-		□ Viral [☐ Other		
Committee Commer	nts:							
Contingent Ite	ems:							
of Tog		e Infecte				idation Proc on Using Pa		Inactivation ences' Cell
Facilities, Procedure			ractices	Rev	iewed (Y/	N):		
⊠ Yes □ No	ĺ				`	,		
PI/Supervisor Train	ing (Y/	N):				Training (Y/N):	
⊠ Yes □ No		П			⊠ Yes	□ No		
Motion:		T.				A hatain.	Daguage	Not
Approved with Contingency		Fo	7	A	gainst: 0	Abstain:	Recuse:	Present:
Basic Research Amendment # 7		col ID: BC019	PI: Ros		BSL-2	ety Level: 2, BSL-2+, BSL-2		H Cat.: III-E
Project Titles:							1	
Influenza virus neutra								
Associated Grant Non-NIH Funding	umbers	S:						
Summary of Approv								
Propagation and gene							s; Transduc	ction of
tissue culture cells; ac Requested Additions			vivo; nu	man-	derived m	aterials.		
Addition of n		_	in vitro s	and ir	n vivo stud	lies		
7 Iddition of h	ev pro	cems for	iii vitio t	411 G 11	1 vivo stat	4105		
Function/Nature of R ⊠ N/A □ Oncogene □ Immunomodulatory	□ Tun	nor Supp	ressor G	ene	☐ Structur	_	_	timicrobial
Species of Recombin ⊠ N/A □ Human □			-		□ Viral [□ Other		

Administrative edits								
1 1011111111111111111111111111111111111								
Facilities, Procedures, and Safety Practices Reviewed (Y/N):								
⊠ Yes □ No								
PI/Supervisor Training (Y/N): Handler Training (Y/N):								
⊠ Yes □ No								
tion:								
Approved with For Against Abstain Recuse	Not							
Administrative Revisions 7 0 1 0	resent:							
	0							
Protocol ID: PI: Biosafety Level: NIH C	at ·							
Basic Research FLIBC026 Ross BSL-1, BSL-2, III-F-8, III-F								
Amendment # 8 BSL-2+, BSL-3, F-3, III-D-7								
ABSL-2, ABSL-3 III-E-								
Project Titles:								
H2 Influenza Virus Infection and Vaccination								
Associated Grant Numbers:								
Non-NIH Funded								
Summary of Approved Items:								
Propagation of H2N2 and H2N3 influenza virus and subsequent assessment in vivo vac	ecinated							
under FLIBC019, human-derived materials.								
Requested Additions/Changes:								
 Addition of H5N1 to the protocol for in vitro and in vivo use 								
Protocol title change								
Function/Nature of Recombinant Genes to be Expressed:								
⊠ N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimic	crobial							
☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Other								
Species of Decembinant Cones to be Evaposed								
Species of Recombinant Genes to be Expressed: ⊠ N/A □ Human □ Murine ⊠ Rat □ Bacterial □ Viral □ Other								
Committee Comments:								
Administrative edits								
Update working procedures for using multiple subtypes Clarific inventors and the subtypes								
Clarify inventory recording Light and Company and American areas and a second a second and								
 Update doffing procedures Facilities, Procedures, and Safety Practices Reviewed (Y/N): 								
Yes No No No No Yes No Yes No Yes No								
PI/Supervisor Training (Y/N): Handler Training (Y/N):								
\boxtimes Yes \square No \boxtimes Yes \square No								
Motion: For: Against: Abstain: Recuse:	Not							
	resent:							

Approved with			0
Administrative Revisions			

IV. Updated SOPs:

SOP a: Disinfectants for Biological Materials	Comments	s: Administra	ative edits	
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP b: BSL-3 Training Procedures	Comments: Administrative edits			
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP c: Agent Inventory	Comments: Administrative edits			
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP d: Policy for HPAI Quarantine	Comments: Clarify definition of "Susceptible			
	Species"			
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP e: Validation Procedures for Formalin	Comments:			
Fixation of Orthomyxoviridae Infected	 Administrative edits 			
Tissues	 Verify viral titer provided 			
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP f: Validation Procedures for Inactivation	Comments:			
of Togaviridae Infected Single Cell	 Administrative edits 			
Suspension Using Parse Biosciences' Cell Fixation Reagent	Update volume amounts and time points			d time
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	0	0

SOP g: Inactivation Procedures for Formalin	Comments:
Fixed Tissues	 Administrative edits
	Contingent Items:

	 Validation of inactivation procedures 			
Motion: Approved with Contingency	For: 8	Against:	Abstain:	Recuse: